Biofrontera (BFRI) Convertible Debt (2024 - 2026)
Biofrontera (BFRI) posted quarterly Convertible Debt of $4.6 million for Q4 2025, up 11.98% year-over-year from $4.1 million in Q4 2024, and up 2.85% quarter-over-quarter from $4.5 million in Q3 2025.
Biofrontera (BFRI) Convertible Debt (2024 - 2026) Analysis & Trends
Biofrontera's Convertible Debt history runs 2 years deep, the most recent figure standing at $4.6 million for Q4 2025.
- In Q4 2025, Convertible Debt rose 11.98% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (up 11.98% YoY), while the FY2025 annual figure was $4.6 million, up 11.98% from the prior year.
- Convertible Debt for Q4 2025 stood at $4.6 million, up from $4.5 million in the prior quarter.
- The five-year high for Convertible Debt was $4.6 million in Q4 2025, with the low at $4.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Biofrontera | 18.87 Mn | 14.16 Mn | 9.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.62 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 4.46 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 4.10 Mn |